Cite
HARVARD Citation
Craig, T. et al. (2022). Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 399 (10328), pp. 945-955. [Online].